Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vir Biotechnology (VIR)

Vir Biotechnology adds Suzanne Topalian to board, expanding it to nine members

Neutral Impact 2 of 5 leadership

Vir Biotechnology's Board increased its size from eight to nine members and appointed Suzanne Topalian, M.D., to fill the new seat, effective October 27, 2026. She also joined the Science and Technology Committee and receives the standard non-employee director compensation, including automatic option and restricted stock unit grants.

Key points

  • Board expanded from eight to nine members; Dr. Topalian named Class III director through the 2028 annual meeting
  • Dr. Topalian appointed to the Science and Technology Committee, effective October 27, 2026
  • She received stock option and restricted stock unit awards under the 2019 Equity Incentive Plan on her appointment date
  • Company has signed its standard indemnity agreement with Dr. Topalian

The filing

CompanyVir Biotechnology (VIR)
Form8-K, current report
Filed with the SECOct 28, 2026, 8:37 AM ET
Accession number0001628280-26-067742

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.